# Prevalence and indicators of HIV and AIDS among adults admitted to medical and surgical wards in Blantyre, Malawi

DK Lewis, M Callaghan, K Phiri, J Chipwete, JG Kublin, E Borgstein, EE Zijlstra

## **Abstract**

Despite high seroprevalence there are few recent studies of the effect of HIV on hospitals in sub-Saharan Africa. We examined 1226 consecutive patients admitted during two 2week periods in October 1999 and January 2000. 70% medical patients were HIV positive, and 45% had AIDS. 36% surgical patients were HIV positive and 8% had AIDS. Seroprevalence rose to a peak among 30-40 year olds; 91% medical, 56% surgical and 80% all patients in this age group were HIV positive. Seropositive women were younger than seropositive men (median age 29 v 35, p<0.0001). Symptoms strongly indicative of HIV were history of shingles, chronic diarrhoea or fever or cough, history of tuberculosis, weight loss, and persistent itchy rash (adjusted odds ratios all over 5). Clinical signs strongly indicative of HIV were oral hairy leukoplakia, shingles scar, Kaposi's sarcoma, oral thrush, and hair loss (adjusted odds ratios all over 10). Of surgical patients with 'deep infections' (breast abscess, pyomyositis, osteomyelitis, septic arthritis, and multiple abscesses), 52% were HIV positive (OR compared with other surgical patients 2.4). Severe bacterial infections, tuberculosis, and AIDS caused 68% deaths. HIV dominates adult medicine, is a major part of adult surgery, is the main cause of death in hospital, and affects the economically active age group of the population.

# Introduction

Sub-Saharan Africa is the region of the world worst affected by the HIV pandemic, with over 28 million people estimated to be living with AIDS, and perhaps 9% of the adult population infected with HIV. Adult HIV seroprevalence in Malawi was estimated to be 15% in 2001 [UNAIDS, 2002]. In 1996, seroprevalence among women at antenatal clinics in Blantyre was 32.8% [Taha et al, 1998]. In 1993 most deaths in the medical wards of Queen Elizabeth Central Hospital, Blantyre, Malawi occurred in young adults, predominantly from tuberculosis (TB), AIDS and gastroenteritis [Harries & Mvula, 1998]. HIV seroprevalence was not measured but mortality had increased compared with the same wards twenty years previously.

Studies from elsewhere in the region have measured seroprevalence among medical admissions [Ankrah et al, 1994; Temba et al, 1994; Colvin et al, 2001]. HIV seroprevalence has risen as the epidemic has worsened – for example, seroprevalence among medical admissions to Kenyatta Hospital, Nairobi rose from 19% in 1988-9 up to 39% in 1992, appearing to stabilise at 40% in 1997 [Arthur et al, 2000]. Others have examined specific wards or diseases: for example 40% of adults admitted to an Infectious Diseases ward in Abidjan in 1991 were HIV positive [Vugia et al, 1993]. Seroprevalence among inpatients with TB, including in Blantyre and Zomba, is as high as 75% [Harries et al, 1995; Grant et al, 1998; Harries et al, 1998]. There is less information about surgical patients. Of 100 adults admitted with long bone fractures in Lusaka in 1992, 32% were HIV

positive, and this was thought to be representative of the general population [Kehoe & Jellis, 1994]. In 1997 seroprevalence on a South African gynaecology ward was 42%, but we found no other studies of HIV prevalence in African surgical patients [Wilkinson et al, 1999].

We aimed to determine the prevalence of HIV infection and AIDS among patients of different ages and diagnoses, and to assess clinical indicators of HIV infection, among medical and surgical inpatients at Queen Elizabeth Central Hospital, Blantyre.

## Materials and Methods

For four weeks (4th to 18th October 1999, and 17th to 31st January 2000) all patients admitted to the adult (13 years and over) surgical and medical wards at QECH were reviewed. A study clinician conducted a standardised history and physical examination. Those who gave written consent had blood taken for HIV testing and were offered post-test counselling. Approval was obtained from the Research Committee of the University of Malawi College of Medicine.

Patient records were examined at discharge or death. For each patient a single, main diagnosis was made. This was the diagnosis thought to be responsible for admission: for example 56 patients had Kaposi's sarcoma (KS) but in only eleven was this the main reason for admission (Table 3). AIDS was defined according to the expanded WHO case definition for AIDS surveillance [WHO, 1994]. For the purposes of this definition only patients with proven TB were classed as having TB, not those with suspected TB under investigation.

Serum was tested with a rapid test (Abbot Determine, Dainabot Company, Tokyo, Japan, or Serocard, Trinity Biotech plc, Dublin, Eire) and an ELISA (Vironostika, Organon Teknika bv, Boxtel, Netherlands, or OrthoHIV1/HIV2, Ortho Diagnostic Systems, Rariton, NJ, USA). Samples testing positive with both the rapid test and the ELISA were regarded as HIV positive.

Data were double-entered into EpiInfo version 6.04b (CDC, USA; WHO, Switzerland) and validated, then analysed with STATA 6.0 (Stata Corporation, Texas 77840, USA). Categorical variables were compared with chi2 or Fisher's exact test. Continuous data were compared with Student's t-test if normally distributed, or Wilcoxon rank-sum test. Odds ratios (OR) were calculated and adjusted (AOR) using logistic regression. Unless stated AOR controlled for age, sex, urban or rural residence, and education level. 95% confidence intervals (CI) are given.

# Results

There were 791 medical admissions during the study periods. Of these, 18 were missed by the study team and four died before assessment. Eleven declined to take part, leaving 758 medical patients who were assessed and gave blood for HIV testing. There were 486 surgical admissions during the study periods, of whom 29 were missed, and 12 declined to take part, leaving 445 included. In total there were 1277 admissions, of whom 1226 were seen, and 1203 consented to an HIV test; 23 (1.9%) declined testing. Of those consenting to the test 148, (12.3%) said that they did not wish to be offered post-test counselling.

Age was the most important demographic factor. 80% of patients aged 31 to 40 years were HIV positive (AOR 15.4, compared with patients aged 13 to 20 years). Overall 70% medical patients were HIV positive, and 45% met the expanded WHO case definition for AIDS surveillance (Table1). Seroprevalence rose to a peak among 31 to 40 year olds (89% in men, 92% in women), and then declined with increasing age.

Malawi Medical Journal 5

The rise occurred earlier in women, and the group of women aged 21 to 30 years had the largest number of HIV positive patients. The pattern of AIDS prevalence was similar, reaching a peak of 66% in those aged 31 to 40 years.

In surgical patients, scroprevalence followed the same pattern as in medical patients, but at lower levels; 36% surgical patients were HIV positive and 8% had AIDS (Table 2). Scropositivity peaked at 65% in women aged 21 to 30, and 58% in men aged 31 to 40.

The median age of seronegative patients was the same (29) in men and women, but female seropositive patients were significantly younger (median age 29 years) than male seropositive patients (median age 35, ranksum p<0.0001).

# HIV and diagnostic group

Most patients with proven or suspected tuberculosis (87%), and with severe bacterial infections (78%) were HIV positive, and most of these met the definition for AIDS. Sixteen patients who were being investigated for chronic cough but did not have TB proven while on the ward, were not classified as AIDS (Table 3). However seroprevalence in suspected TB was the same (87%) as in proven TB. Patients with acute gastroenteritis had a high prevalence of HIV (81%) but a relatively low prevalence of AIDS (34%).

All but one of the patients admitted primarily with Kaposi's sarcoma were HIV positive, and by definition had AIDS. Relatively few of the other surgical patients had AIDS. Among other surgical patients those with infections had the highest HIV prevalence (48%). These include superficial infections (wound infections, abscesses of the fingers and toes, lymphadenitis), so we separated those with 'deep infections' (breast abscess, pyomyositis, osteomyelitis, septic arthritis, and multiple abscesses), and compared them with all other surgical patients except those admitted with Kaposi's sarcoma. Of those with deep infections 52.2% were HIV positive (versus 31.2%, p=0.001). OR for being HIV positive if admitted with a deep infection was 2.4 (95% CI 1.4 to 4.1, AOR 2.1, p=0.01).

Seroprevalence among trauma patients was 29%, and we found no significant differences according to the type of trauma (assault, road traffic accident, burn, or other accident). The predominant type of trauma was road traffic accidents (41% and 39% of trauma in men and women respectively), and 70% trauma admissions were men. However, among trauma patients more women were HIV positive than men (41% v 24%, p=0.029). OR for being HIV positive if a female trauma patient, compared with male trauma patients, was 2.2 (p=0.031, 95% CI 1.1 to 4.5, unaltered by adjustment).

# **Duration of admission and mortality**

HIV positive medical patients had a slightly longer length of stay than HIV negative patients (median days in hospital 3 v 2.5, ranksum p<0.0001), and seronegative patients died earlier in the admission (median day of death, Day 2) than seropositive patients (median Day 4, p=0.006). There was no difference in the length of stay (median 3 days) of HIV positive and negative surgical patients.

Seventeen surgical patients (4.7%) died in hospital (of whom two who did not have HIV testing), and they were more likely to be HIV positive than negative (OR 3.7, p=0.02, 95% CI 1.2 to 11; AOR 4.3). One third of the surgical deaths occurred among patients aged 31 to 40 years. Over half the deaths were in trauma patients (eight), with four deaths among patients with surgical sepsis, four with KS, and one other.

121 (15.7%) medical patients died: 96 of 530 (18.1%)

seropositive, and 25 of 228 (11.0%) seronegative (p=0.014). OR for dying if seropositive was 1.8 (95% CI 1.1 to 2.9. AOR 2.1, p=0.003, 95% CI 1.3 to 3.5). Among seropositive patients with AIDS 70 of 340 (20.9%) died, compared with 25 of 190 (13.2%) without AIDS (OR 1.7, p=0.028, 95% CI 1.1 to 2.9; AOR 1.7). The proportion of patients dying in each age group was similar in those over 30 years (about 20%), and lower in the younger patients; but the majority of deaths occurred in the 21-40 year olds (57% all medical deaths). Severe bacterial infections (40%), TB (16%), and AIDS defining illnesses (12%) accounted for most deaths.

There was a striking difference in mortality between men and women on the medical wards. 22.3% men died compared with 9.7% women (OR if male 2.7, p<0.001, 95% CI 1.8 to 4.0), and this was unaffected by adjustment for age, urban residency, education level, and HIV seropositivity or AIDS. Most of the excess deaths appeared to be from severe bacterial infections, even though there were fewer men than women admitted with these.

# Clinical indicators of HIV seropositivity

Table 4 shows clinical indicators of HIV. The demographic variables of age, sex, urban or rural residence and education level were confounding factors, so the odds ratios are adjusted for those, but controlling in addition for literacy did not alter the adjusted odds ratios. The most important demographic factor was age, as described above. Being female, living in urban areas, increased education level, and being married (compared with not living with a partner at present) were all indicators of seropositivity. Having been divorced or separated ever, and being widowed if under 40, were strongly associated with HIV.

Many factors in the medical history were strong predictors of HIV infection. The most important were a history of shingles (AOR 16.3), tuberculosis, chronic (> 1 month) diarrhoea or fever or cough, weight loss, and a persistent itchy rash. More than 83% patients with any one of these were HIV positive. Clinical signs were better indicators of seropositivity, although most signs were less frequent than the symptoms or past illnesses mentioned. All 16 patients with oral hairy leukoplakia were HIV positive, as were all except one of 44 with oral KS, and all except two of 86 with a shingles scar (OR 35.9). Other predictive signs were skin KS, oeasophageal candidiasis, oral thrush, and abnormal hair loss. All of these signs on their own were more specific indicators of HIV infection than the (not expanded) WHO case definition for AIDS surveillance (which does not rely on HIV testing). Of 360 patients who met this definition, 13.6% were HIV negative, and 29.4% did not meet the criteria of the expanded WHO definition.

# Discussion

We examined 1203 adults admitted to medical and surgical wards in Blantyre. As shown previously [Harries et al, 1995] confidential HIV testing was acceptable to almost all patients (98.1%), and most wished to be offered their results. We found that 70% medical patients and 36% surgical patients were HIV positive; 45% medical patients had clinical AIDS, but relatively few surgical patients did. We believe that this is the highest prevalence of HIV recorded on a general medical ward.

Most deaths were HIV and AIDS related, and affected young, potentially economically active adults. HIV positive women were approximately six years younger than HIV positive men, as has been found in Kenya and Uganda. [Tembo et al, 1994, Arthur et al, 2000]. There is anecdotal evidence that the widowers of HIV infected women choose younger women as

Malawi Medical Journal

their new sexual partners [Nunn et al, 1996]. It is difficult to explain the large difference in mortality between men and women: fewer men were admitted but more died. It is possible that very sick women (whose relatives expect that death is inevitable) are not brought to hospital for cultural reasons mainly that a family will go to greater effort to find money to transport a sick man who is the main income generator. However that would result in fewer female admissions because the sickest women are not brought to hospital, and this does not appear to be the case. In most of sub-Saharan Africa HIV prevalence is higher among women, but what evidence there is indicates more rapid recent increases in male adult mortality, implying that the impact of the epidemic on men is more severe [Gregson & Garnett, 2000]. It has been suggested that women are infected younger and have slower disease progression than men. Perhaps, with their longer survival time, women are admitted more often with HIV related illnesses earlier in the course of their disease.

Medical diagnoses particularly associated with HIV (other than AIDS defining conditions) were TB [Tembo et al, 1994, Harries et al, 1995], severe bacterial infections [Gilks et al, 1990], and acute diarrhoea.[Gilks et al, 1992, Tembo et al, 1994, Arthur et al, 2000]. Of these conditions, patients with diarrhoea were less likely to meet the criteria for AIDS. Diarrhoea may represent enteric fever-like illness [Gilks et al, 1992], and perhaps many of these patients were admitted with non-typhi salmonella bacteraemia as their first HIV related illness.

Among surgical patients we found those with severe infections (mainly breast abscesses, pyomyositis, and multiple abscesses), were twice as likely as others (AOR 2.1) to have HIV. We expected that trauma patients would have a similar seroprevalence to that of the general population, yet 41% women admitted with trauma were HIV positive, and they were more likely than men admitted with trauma (AOR 2,2) to be seropositive. We do not know if this is an artefact caused by a small number (46 women, 95% CI for seropositivity 27 to 56%), or if women susceptible to trauma are for some reason at greater risk of HIV infection than other women, perhaps because of more risk taking behaviour. Women at antenatal clinic have a slightly lower seroprevalence than the general population because of reduced fertility with HIV infection, but the difference is unlikely to be more than a few percent [Kweisgabo et al, 2000, Zaba et al, 2000]. The antenatal figure of 33% in urban Malawi [Taha et al, 1998] is probably a reasonable estimate of the population seroprevalence in women of childbearing age.

As found elsewhere, seroprevalence rose with increased education [Dallabetta et al, 1993, Chao et al, 1994, Taha et al, 1998], and in urban patients [Mnyika et al, 1994]. We found that living with a sexual partner at present, having been divorced ever, and if aged under 40 being widowed, were all associated with HIV infection. A history of shingles, TB, weight loss, itchy rash, and chronic symptoms of diarrhoea, fever or cough were strongly associated with HIV. Many clinical signs were indicators of seropositivity, but oral hairy leukoplakia was pathognomonic, and disseminated KS or a shingles scar were almost pathognomonic. A history of shingles may be less reliable as a marker of actually having had shingles than finding a scar. More than 90% of patients with any one of these signs, or oral thrush or abnormal hair loss, were HIV positive. In this setting these signs individually were more specific predictors than fulfilling the criteria of the WHO case definition for AIDS surveillance, although the case definition was more sensitive than any single sign. Our results are compatible with those of a community cohort in Uganda, where shingles, oral thrush and pulmonary TB were highly predictive of HIV infection [Morgan et al, 2002].

The situation in Blantyre is likely to be similar to that in many other countries in sub-Saharan Africa, where population prevalence of HIV is the same or higher. In this setting HIV and AIDS dominate adult medicine, and are a significant factor in adult surgery. HIV is the main cause of death in patients admitted to hospital, and affects the section of the population which should be the most economically active.

#### Acknowledgements

This study was supported by the Malawi Health Support Fund of the Royal Netherlands Embassy, Lusaka, grant MW004205. We would like to thank: laboratory staff who performed HIV testing, especially Clyton Munthali; Henry Epino and Jolien Bueno de Mesquito for data entry; Dr Martin Boeree for help planning the study; and Professor Malcolm Molyneux for advice during the study and for reviewing the manuscript.

David K Lewis, Maria Callaghan, Kamija Phiri, James Chipwete, James G Kublin, Eric Borgstein, Ed E Zijlstra

University of Malawi College of Medicine, Private Bag 360, Chichiri, Blantyre 3. Author for correspondence: Dr DK Lewis

Email: mariadavid@callaghanlewis.fsnet.co.uk

#### References

Ankrah TC, Roberts MA, Antwi P, et al. (1994) The African AIDS case definition and HIV serology in medical in-patients at Komfo Anokye Teaching Hospital, Kumasi, Ghana. W Afr Med J, 13, 98-101.

Arthur G, Bhatt SM, Muhindi D, Achiya GA, Kariuki AM, Gilks CF. (2000) The changing impact of HIV/AIDS on Kenyatta National Hospital, Nairobi from 1988/89 through 1992 to 1997. AIDS, 14,1625-1631.

Chao A, Bulterys M, Musanganire F, et al. (1994) Risk factors associated with prevalent HIV-1 infection among pregnant women in Rwanda. Int J Epidemiol, 23, 371-380.

Colvin M, Dawood S, Kleinschmidt I, Mullick S, Lallo U. (2001) Prevalence of HIV and HIV-related diseases in the adult medical wards of a tertiary hospital in Durban, South Africa. Int J STD AIDS ,12, 386-389.

Dallabetta GA, Miotti PG, Chiphangwi JD, et al. (1993) High socioeconomic status is a risk factor for Human Immunodeficiency Virus type 1 (HIV-1) infection but not for sexually transmitted diseases in women in Malawi: implications for HIV-1 control. J Infect Dis, 167, 36-42.

Gilks CF, Brindle RJ, Otieno LS, et al (1990). Life threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet, 336, 545-9.

Gilks CF, Otieno LS, Brindle RJ, et al. (1992). The presentation and outcome of HIV-related disease in Nairobi. OJM, 297, 25-32.

Gregson S, Garnett GP (2000). Contrasting gender differentials in HIV-1 prevalence and associated mortality increase in eastern and southern Africa: artefact of data or natural course of epidemics? AIDS, 14(suppl 3), S85-S99.

Grant AD, Sidibe K, Domoua K, et al (1998). Spectrum of disease among HIV-infected adults hospitalised in a respiratory medicine unit in Abidjan, Cote d'Ivoire. Int J Tuberc Lung Dis, 2, 926-934.

Harries AD, Mvula B. (1995) The changing pattern of mortality in an African medical ward. Trop Geograph Mcd, 47, 171-174.

Harries AD, Maher D, Mvula B, Nyangulu D. (1995). An audit of HIV testing and HIV serostatus in tuberculosis patients, Blantyre, Malawi. Tuberc Lung Dis, 76, 413-417.

Harries AD, Nyangulu DS, Kang'ombe C, et al (1998). Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba hospital, Malawi. Trans R Soc Trop Med Hyg, 92, 343-7.

Kehoc NJS, Jellis JE (1994). The incidence of the human immunodeficiency virus in injured patients in Lusaka. Injury, 25, 375-378.

Kweisgabo G (1999). Prevalence of HIV infection among hospital patients in North West Tanzania. AIDS Care, 11, 87-93.

Kweisgabo G, Killewo JZ, Urassa W, et al (2000). Monitoring of HIV-1 infection prevalence and trends in the general population using pregnant women as a sentinel population: 9 years experience from the Kagera region of Tanzania. J Acq Immune Defic Synd, 23, 410-7.

Malin AS, Gwanzura LKZ, Klein S, Robertson VJ, Musvaire P, Mason PR (1995). Pneumocystis carinii pneumonia in Zimbabwe. Lancet, **346**, 1258-61.

Mnyika KS, Klepp K-İ, Kvale G, Nilssen S, Kissila PE, Ole-King'ori N (1994). Prevalence of HIV-1 infection in urban, semi-urban and rural areas in Arusha region, Tanzania. AIDS, 8, 1477-81.

Morgan D, Mahe C, Mayanja B, Whitworth JAG (2002). Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. BMJ, **324**,

Nunn AJ, Mulder DW, Kamali A, Kenyega-Kayondo J-F, Whitworth JAG (1996). HIV-1 incidence in sub-Saharan Africa. Lancet, 348, 833-4.

Taha TE, Dallabetta GA, Hoover DR, et al (1998). Trends of HIV-1 and sexually transmitted diseases among pregnant and postpartum women in urban Malawi. AIDS, **12**, 197-203. Tembo G, Friesan H, Asiimwe-Okiror G, et al (1994). Bed occupancy due to HIV/AIDS in an urban hospital medical ward in Uganda. AIDS, **8**, 1169-1171.

UNAIDS / WHO (2002). Report on the global HIV / AIDS epidemic, 2002. UNAIDS, Geneva, Switzerland.

http://www.unaids.org/barcelona/presskit/barcelona%20report/table.html

Vugia DJ, Kiehlbauch JA, Yeboue K, et al (1993). Pathogens and predictors of fatal septicemia associated with human immunodeficiency virus infection in Ivory Coast, West Africa. J Infect Dis, **168**, 564-70.

Wilkinson D, Wilkinson NF, Connolly C (1999). HIV infection among women admitted to the gynaecology service of a district hospital in South Africa. Int J STD AIDS, 10, 735-7. World Health Organisation. (1994). WHO case definitions for AIDS surveillance in adults and adolescents. Weekly Epidemiological Record, 69, 273-5.

Zaba B, Boerma T, White R (2000). Monitoring the HIV epidemic using HIV prevalence data among young women attending antenatal clinics: prospects and problems. AIDS, 14, 1633-45.

	Age group	13-20y	21-30y	31-40y	41-50 y	51-60y	Over 60y	All ages
Men	number HIV positive / n	5 / 26	86 / 125	89 / 100	50 / 66	18 / 24	4 / 22	252 / 363
	% (95% CI)	19 (3 to 35)	69 (61 to 71)	89 (83 to 95)	76 (65 to 86)	75 (56 to 94)	18 (1 to 36)	69 (65 to 74)
	% age group with 'AIDS'	0	46 (38 to 55)	66 (57 to 75)	42 (30 to 55)	46 (24 to 67)	9 (1 to 22)	45 (40 to 51)
	(95% CI)							
Women	number HIV positive / n	30 / 64	131 / 161	73 / 79	26 / 40	15 / 29	3 / 22	278 / 395
	% (95% CI)	47 (34 to 59)	81 (75 to 87)	92 (86 to 98)	65 (50 to 80)	52 (32 to 71)	14 (2 to 29)	70 (66 to 75)
	% age group with 'AIDS'	20 (10 to 30)	50 (42 to 57)	66 (55 to 77)	48 (31 to 64)	34 (16 to 53)	5 (1 to 14)	44 (39 to 49)
	(95% CI)							
All	number HIV positive (n)	35 / 90	217 / 286	162 / 179	76 / 106	33 / 53	7 / 44	530 / 758
	% (95% CI)	39 (29 to 49)	76 (71 to 81)	91 (86 to 95)	72 (63 to 80)	62 (49 to 76)	16 (5 to 27)	70 (67 to 73)
	% age group with 'AIDS'	14 (7 to 22)	48 (42 to 54)	66 (59 to 73)	44 (35 to 54)	40 (26 to 53)	7 (1 to 15)	45 (41 to 48)
	(95% CI)							

Table 1. Proportion of medical patients HIV positive and with clinical AIDS (Expanded WHO case definition for AIDS surveillance), by age group and sex. n is total number of patients in the age group.

	Age group	13-20y	21-30y	31-40y	41-50 y	51-60y	Over 60y	All ages
Men	number HIV positive / n	4 / 58	28 / 82	34 / 59	8 / 26	10 / 30	4 / 24	88 / 280*
	% (95% CI)	7 (2 to 14)	34 (24 to 45)	58 (45 to 71)	31 (12 to 50)	33 (15 to 51)	17 (1 to 33)	31 (26 to 37)
	% age group with 'AIDS'	0	5 (1 to 10)	10 (2 to 18)	8 (1 to 19)	3 (1 to 21)	4 (1 to 13)	6 (3 to 8)
	(95% CI)							
Women	number HIV positive / n	8 / 37	39 / 60	14 / 26	5 / 19	3 / 11	0 / 11	69 / 165*
	% (95% CI)	22 (8 to 36)	65 (53 to 77)	54 (33 to 74)	26 (5 to 48)	27 (1 to 59)	0	42 (34 to 50)
	% age group with 'AIDS'	8 (1 to 17)	15 (6 to 24)	12 (1 to 25)	11 (1 to 26)	9 (1 to 29)	0	11 (6 to 16)
	(95% CI)							
All	number HIV positive (n)	12 / 95	67 / 142	48 / 85	13 / 45	13 / 41	4/ 35	158 / 445 *
	% (95% CI)	13 (6 to 19)	47 (39 to 55)	56 (46 to 67)	29 (15 to 43)	32 (17 to 47)	11 (1 to 23)	36 (31 to 40)
	% age group with 'AIDS'	3 (1 to 7)	9 (4 to 14)	11 (4 to 17)	9 (1 to 17)	10 (1 to 19)	3 (1 to 8)	8 (5 to 10)
	(95% CI)							

Table 2. Proportion of surgical patients HIV positive and with clinical AIDS (Expanded WHO case definition for AIDS surveillance), by age group and sex. n is total number of patients in the age group.

\* One man's (HIV negative) and one woman's (HIV positive) age were not known

Diagnostic group	Number HIV positive /n	% HIV	% AIDS
AIDS defining illnesses*	62 / 65	95	89
Tuberculosis (proven or suspected)	94 / 108	87	75
Acute gastroenteritis	65 / 80	81	34
Severe bacterial infections**	151 / 193	78	62
Other febrile illness (malaria or no definite diagnosis)	79 / 126	63	21
Other medical problem (eg heart failure, stroke, diabetes, liver			;
disease, gastrointestinal bleed, poisoning)	79 / 186	42	-15
Total Medical patients	530 / 758	70	45
Kaposi's sarcoma	10 / 11	91	91
'Surgical sepsis' ***	67 / 141	48	11
Trauma	48 / 166	29	2
Other surgical problem (eg elective operation, cancer except Kaposi's)	29 / 116	25	4
Total Surgical patients (no diagnosis in 11 patients)	158 / 445	36	8

Table 3. Patients HIV positive by diagnostic group. Diagnosis is the main reason for admission only (one diagnosis per patient).

Malawi Medical Journal

<sup>\*</sup> AIDS defining illnesses are cryptococcal meningitis (india-ink positive CSF), Kaposi's sarcoma (obvious widespread clinical KS), chronic diarrhoea, presumptive Pneumocystis carinii pneumonia (typical symptoms and chest x-ray changes [Malin et al, 1995]), wasting syndrome and oesophageal thrush (oral thrush plus painful dysphagia). The three sero-negative patients in this category were two with chronic diarrhoea, and one with oral thrush and painful dysphagia.

<sup>\*\*</sup> Severe bacterial infections include pneumonia, meningitis, septicaemia and empyema.

<sup>\*\*\* &#</sup>x27;Surgical sepsis' is abscesses or pus requiring surgical drainage, anorectal disease, and wound or bone or joint infections

Demographies   Age   1-2 Oyears   185   25	Clinical Indicator	Number with indicator	positive	P	Odds Ratio	[95% CI]	Adjusted OR	[95% CI]	P
Age 14-20 years   185   25	Demographics	mulcator							
Age 21 – 30 years 428 66		185	25		1		1		
Age 31 - 40 years         264         80         < 0.001         11.4         [7.3 to 17.8]         15.4         [9.5 to 24.9]            Age 31 - 50 years         15         9         -0.001         4.2         [2.7 to 6.7]         6.2         [3.8 to 10.3]            Age 51 - 60 years         94         49         -0.001         2.8         [1.7 to 4.7]         4.3         [2.4 to 7.7]            Age over 60 years         79         14         0.002         0.48         [0.23 to 0.97]         0.58         [0.25 to 1.4]         0           Urban         785         61%         -0.001         1.5         [1.2 to 1.8]         1.5         [1.2 to 2.0]         0           Urban         785         64%         -0.001         1.6         [1.3 to 2.0]         1.5         [1.2 to 2.0]         0           Liferate         87         59%         0.46         0.86         [0.5 to 1.3]         1.3         [1 to 1.8]         0           Walcowed         70         0.00         0.06         1.4         [1.1 to 1.8]         1.6         [1.2 to 2.0]         0           Widowed fund         70         2.00         8.4         [3.3 to 21.2]         3.7 <th< td=""><td></td><td></td><td></td><td>&lt; 0.001</td><td></td><td>[3.9 to 8.5]</td><td>6.9</td><td>[4.6 to 10.5]</td><td>&lt; 0.001</td></th<>				< 0.001		[3.9 to 8.5]	6.9	[4.6 to 10.5]	< 0.001
Age 41 - 50 years         151         59 <a href="color: note;">0.0001         4.2         [2.7 to 6.7]         6.2         [3.8 to 10.3]          Age 51 - 60 years         94           Age over 60 years         99         14         0.042         0.48         [0.23 to 0.97]         0.58         [0.25 to 1.4]           Age over 60 years         79         14         0.042         0.48         [0.23 to 0.97]         0.58         [0.25 to 1.4]          Class         Class         (2.7 to 0.00)         1.5         [1.2 to 0.2]          Class         Class         (2.2 to 0.7)         50         0.001         1.6         [1.3 to 2.0]         1.5         [1.2 to 2.0]          Class         8.7 to 0.001         1.7         [1.4 to 2.2]         1.7         [1.3 to 2.3]          Class         8.2 to 0.001         1.7         [1.4 to 2.2]         1.7         [1.3 to 2.3]          Class         8.2 to 4.0         0.000         1.8         [2.1 to 3.8]         3.4         [2.5 to 4.7]         V.0         Class         0.000         1.7         [1.4 to 2.2]         1.7         [1.3 to 2.3]         Class         0.000         1.8         [2.1 to 3.8]         3.4         [2.5 to 4.7]</a>								[9.5 to 24.9]	< 0.001
Age 51 - 60 years         94         49         <0.001         2.8         [1.7 to 4.7]         4.3         [2.4 to 7.7]            Age over 60 years         79         14         0.042         0.948         [0.23 to 0.97]         0.58         [0.25 to 1.4]         0           Urban         785         61%         <0.000         1.5         [1.2 to 1.8]         1.5         [1.2 to 2.0]            Urban         785         61%         <0.000         1.5         [1.2 to 1.8]         1.5         [1.2 to 2.0]            Urban         785         61%         <0.000         1.7         [1.4 to 2.2]         1.7         [1.3 to 2.3]           Married (now)         710         60%         0.006         1.4         [1.1 to 1.8]         1.6         [1.2 to 2.0]            Divorced or separated (ever)         71         60%         0.006         1.4         [1.3 to 2.3]         3.4         [2.5 to 4.7]            Widowed (ever)         174         62%         <0.001         8.4         [3.3 to 21.2]         3.7         [1.4 to 9.8]         0.0           Medical History         80         95%         <0.001         6.2         (7.1 to 37.1)								[3.8 to 10.3]	< 0.001
Age over 60 years   Pg									< 0.001
Female								-	0.211
Urban									< 0.001
Literate   887   59%   0.46   0.86   0.56 to 1.3   1.3   1 to 1.8   0									0.001
Syears or more education   Solid   S								-	0.046
education 561 64%		007	3770	0.40	0.00	[0.50 to 1.5]	11.5	[1 to 1.0]	0.010
Married (now)   710   60%   0.006   1.4           1.1 to 1.8       1.6	•	561	64%	<0.001	1 7	[1.4 to 2.2]	1.7	[1.3 to 2.3]	< 0.001
Divocated or separated (ever)   297   75%   0.001   2.8   (2.1 to 3.8]   3.4   (2.5 to 4.7]   <									< 0.001
Separated (ever)   277   75%   -0.001   2.8   [2.1 to 3.8]   3.4   [2.5 to 4.7]   <	, ,	710	00 /0	0.000	1.7	[1.1 to 1.0]	1.0	[1.2 to 2.0]	<b>\0.001</b>
Widowed (ever)   174   62%   0.16   1.3   [0.93 to 1.8]   1.3   [0.93 to 1.9]   0		207	75%	<0.001	28	[2.1 to 3.8]	3.4	[2.5 to 4.7]	< 0.001
Widowed if under age 40   58   92%   <0.001   8.4   [3.3 to 21.2]   3.7   [1.4 to 9.8]   0.001	• '								0.12
Medical History	` , ,	174	0270	0.10	1.5	[0.93 to 1.6]	1.5	[0.93 to 1.9	0.12
Shingles		58	92%	< 0.001	8.4	[3.3 to 21.2]	3.7	[1.4 to 9.8]	0.008
Shingles   115   95%   <0.001   16.2   (7.1 to 37.1)   16.3   (7.1 to 37.5)   <	Medical History								
Diarrhoea over		115	95%	< 0.001	16.2	[7.1 to 37.1]	16.3	[7.1 to 37.5]	< 0.001
Imonth   120   91%   0.001   8.7   [4.6 to 16.4]   9.0   [4.8 to 17.0]   < Tuberculosis   140   89%   0.001   7.4   [4.3 to 12.8]   7.6   [4.4 to 13.2]   < Weight loss   444   82%   0.001   5.6   [3.0 to 10.3]   5.6   [3.0 to 10.5]   < Tuberculosis   448   82%   0.001   5.6   [3.0 to 10.3]   5.6   [3.0 to 10.5]   < Tuberculosis   448   82%   0.001   5.4   [3.3 to 7.9]   5.6   [3.8 to 8.1]   < Tuberculosis   448   86%   0.001   5.4   [3.3 to 6.9]   5.2   [3.5 to 7.4]   < Tuberculosis   448   86%   0.001   4.8   [3.4 to 6.9]   5.2   [3.5 to 7.4]   < Tuberculosis   448   86%   0.001   4.0   [2.7 to 6.1]   4.1   [2.7 to 6.2]   < Tuberculosis   448   68%   0.001   4.0   [2.7 to 6.1]   4.1   [2.7 to 6.2]   < Tuberculosis   448   68%   0.001   4.0   [2.7 to 6.1]   4.1   [2.7 to 6.2]   < Tuberculosis   448   68%   0.001   3.2   [2.2 to 4.6]   3.7   [2.2 to 4.7]   < Tuberculosis   448   68%   0.001   3.0   [2.4 to 3.9]   3.4   [2.6 to 4.4]   < Tuberculosis   448   68%   0.001   3.0   [2.4 to 3.9]   3.4   [2.6 to 4.4]   < Tuberculosis   479   72%   0.001   3.0   [2.4 to 3.9]   3.4   [2.6 to 4.4]   < Tuberculosis   479   72%   0.001   2.9   [2.3 to 3.7]   2.8   [2.2 to 3.6]   < Tuberculosis   478   0.001   2.9   [2.3 to 3.7]   2.8   [2.2 to 3.6]   < Tuberculosis   478   0.001   2.3   [1.5 to 3.5]   2.4   [1.5 to 3.7]   < Tuberculosis   478   0.001   2.3   [1.5 to 3.5]   2.4   [1.5 to 3.7]   < Tuberculosis   478   0.001   2.3   [1.5 to 3.5]   2.4   [1.5 to 3.7]   < Tuberculosis   478   0.001   2.5   [1.2 to 1.9]   1.5   [1.2 t						F		,	
Tuberculosis   140   89%   <0.001   7.4   (4.3 to 12.8)   7.6   (4.4 to 13.2)   <		120	91%	< 0.001	8.7	[4.6 to 16.4]	9.0	[4.8 to 17.0]	< 0.001
Weight loss									< 0.001
Persistent itchy rash 92 87%									< 0.001
Fever over I month 243 84% < 0.001 5.4 [3.8 to 7.9] 5.6 [3.8 to 8.1] < Cough over I month 237 83% < 0.001 4.8 [3.4 to 6.9] 5.2 [3.6 to 7.4] < Cough over I month 237 83% < 0.001 4.8 [3.4 to 6.9] 5.2 [3.6 to 7.4] < Cough over I month 237 83% < 0.001 4.8 [3.4 to 6.9] 5.2 [3.6 to 7.4] < Cough over I month 237 83% < 0.001 4.0 [1 to 20.6] 4.4 [0.97 to 19.8] 0								. ,	< 0.001
Cough over 1 month 237 83% < 0.001 4.8 [3.4 to 6.9] 5.2 [3.6 to 7.4] < 6   Meningitis 14 86% 0.047 4.6 [1 to 20.6] 4.4 [0.97 to 19.8] 0 Genital ulcer (ever) 171 82% < 0.001 4.0 [2.7 to 6.1] 4.1 [2.7 to 6.2] < 6   Genital discharge (ever) 187 78% < 0.001 3.2 [2.2 to 4.6] 3.7 [2.2 to 4.7] < 8   Genital discharge (ever) 187 78% < 0.001 3.0 [2.4 to 3.9] 3.4 [2.6 to 4.4] < 8   Genital discharge (ever) 187 78% < 0.001 3.0 [2.4 to 3.9] 3.4 [2.6 to 4.4] < 8   Genital discharge (ever) 187 88	*								< 0.001
Meningitis								-	< 0.001
Genital ulcer (ever) 171 82% < 0.001 4.0 [2.7 to 6.1] 4.1 [2.7 to 6.2] < 0.001 d.0 [2.7 to 6.1] 4.1 [2.7 to 6.2] < 0.001 d.0 [2.7 to 6.1] 4.1 [2.7 to 6.2] < 0.001 d.0 [2.7 to 6.1] 4.1 [2.7 to 6.2] < 0.001 d.0 [2.7 to 6.1] 4.1 [2.7 to 6.2] < 0.001 d.0 [2.2 to 4.6] 3.7 [2.2 to 4.7] < 0.001 d.0 [2.2 to 4.6] 3.7 [2.2 to 4.4] < 0.001 d.0 [2.4 to 3.9] 3.4 [2.6 to 4.4] < 0.001 d.0 [2.9 to 2.1] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] < 0.001 d.0 [2.9 to 3.7] 2.8 [2.2 to 3.6] d.0 [2.9 to 3.7] 2.9 to 3.7 [2.9 to 3.4] 4.1 to 3.7 [2.9 to 3.4] 4.1									0.055
Genital discharge (ever) 187 78% <0.001 3.2 [2.2 to 4.6] 3.7 [2.2 to 4.7] < Daily activity impaired* 479 72% <0.001 3.0 [2.4 to 3.9] 3.4 [2.6 to 4.4] < Fever this illness or admission 538 71% <0.001 2.9 [2.3 to 3.7] 2.8 [2.2 to 3.6] < Pneumonia 114 74% <0.001 2.3 [1.5 to 3.5] 2.4 [1.5 to 3.7] < Night sweats 219 84% 0.001 1.5 [1.2 to 1.9] 1.5 [1.2 to 1.9] < Abscess / drainage of pus 103 64% 0.15 1.4 [0.9 to 2.1] 1.4 [0.89 to 2.1] 0.  Clinical Signs  Oral Hairy leukoplakia 16 100% <0.001 • Shingles scar 86 98% <0.001 35.9 [8.8 to 147] 34.9 [4.8 to 255] < Oral Kaposi's sarcoma 44 98% <0.001 34.8 [8.8 to 147] 34.9 [4.8 to 255] < Sarcoma 27 96% 0.003 20.3 [2.7 to 150] 19.3 [2.6 to 143] 0.  Oesophageal thrush** 61 93% <0.001 11.5 [4.2 to 32] 11.3 [4.1 to 32] < Oral thrush 166 92% <0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0.  Diffuse meauloopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] <	•							- "	< 0.001
(ever) 187 78% < 0.001 3.2 [2.2 to 4.6] 3.7 [2.2 to 4.7] <   Daily activity impaired   479 72% < 0.001 3.0 [2.4 to 3.9] 3.4 [2.6 to 4.4] <   Fever this illness   or admission   538 71% < 0.001 2.9 [2.3 to 3.7] 2.8 [2.2 to 3.6] <   Feurmonia   114 74% < 0.001 2.3 [1.5 to 3.5] 2.4 [1.5 to 3.7] <   Right sweats   219 84% 0.001 1.5 [1.2 to 1.9] 1.5 [1.2 to 1.9]   Abscess /   Arainage of pus   103 64% 0.15 1.4 [0.9 to 2.1] 1.4 [0.89 to 2.1] 0.  Clinical Signs  Oral Hairy   leukoplakia   16 100% < 0.001   Shingles scar   86 98%	, ,	1/1	8270	<0.001	4.0	[2.7 to 0.1]	4.1	[2.7 to 0.2]	<0.001
Daily activity impaired* 479 72% <0.001 3.0 [2.4 to 3.9] 3.4 [2.6 to 4.4] <		107	790%	-0.001	2.2	[2.2 to 4.6]	2.7	[2 2 to 4.7]	< 0.001
impaired* 479 72% <0.001 3.0 [2.4 to 3.9] 3.4 [2.6 to 4.4] < Fever this illness or admission 538 71% <0.001 2.9 [2.3 to 3.7] 2.8 [2.2 to 3.6] < Free remains or admission 538 71% <0.001 2.9 [2.3 to 3.7] 2.8 [1.5 to 3.7] < Free remains 114 74% <0.001 2.3 [1.5 to 3.5] 2.4 [1.5 to 3.7] < Free remains 219 84% 0.001 1.5 [1.2 to 1.9] 1.5 [1.2 to 1.9] < Free remains 219 84% 0.001 1.5 [1.2 to 1.9] 1.5 [1.2 to 1.9] < Free remains 219 84% 0.001 1.5 [1.2 to 1.9] 1.5 [1.2 to 1.9] < Free remains 219 84% 0.001 1.5 [1.4 [0.9 to 2.1] 1.4 [0.89 to 2.1] 0.0    Clinical Signs  Oral Hairy  leukoplakia 16 100% <0.001    Shingles scar 86 98% 0.001 35.9 [8.8 to 147] 34.9 [4.8 to 255] <  Foral Kaposi's sarcoma 44 98% 0.001 34.8 [8.8 to 147] 34.9 [4.8 to 255] <  Skin Kaposi's sarcoma 27 96% 0.003 20.3 [2.7 to 150] 19.3 [2.6 to 143] 0.0    Oesophageal thrush ** 61 93% 0.001 11.5 [4.2 to 32] 11.3 [4.1 to 32] <  Oral thrush 166 92% 0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] <  Hair loss (not male pattern) 110 92% 0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] <  WHO case definition *** 360 86% 0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] <  Looks wasted 379 83% 0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] <  Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0.0    Diffuse maculopapular rash 95 86% 0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] <  ≥ 38.0 degrees C 324 74% 0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] <  Second 1.5 to 2.5 to 3.4   2.5		107	1070	<0.001	3.2	[2.2 to 4.0]	3.7	[2.2 10 4.7]	<0.001
Fever this illness or admission 538 71% <0.001 2.9 [2.3 to 3.7] 2.8 [2.2 to 3.6] < Pneumonia 114 74% <0.001 2.3 [1.5 to 3.5] 2.4 [1.5 to 3.7] < Significant Signs		470	720%	-0.001	2.0	[2.4 to 2.0]	2.4	F2.6 to 4.41	< 0.001
or admission 538 71% < 0.001 2.9 [2.3 to 3.7] 2.8 [2.2 to 3.6] < Pneumonia 114 74% < 0.001 2.3 [1.5 to 3.5] 2.4 [1.5 to 3.7] < Night sweats 219 84% 0.001 1.5 [1.2 to 1.9] 1.5 [1.2 to 1.9] < Abscess / drainage of pus 103 64% 0.15 1.4 [0.9 to 2.1] 1.4 [0.89 to 2.1] 0  Clinical Signs  Oral Hairy leukoplakia 16 100% < 0.001 • Shingles scar 86 98% < 0.001 35.9 [8.8 to 147] 34.9 [4.8 to 255] < Oral Kaposi's sarcoma 44 98% < 0.001 34.8 [8.8 to 147] 34.9 [4.8 to 255] < Skin Kaposi's sarcoma 27 96% 0.003 20.3 [2.7 to 150] 19.3 [2.6 to 143] 0  Oesophageal thrush ** 61 93% < 0.001 11.5 [4.2 to 32] 11.3 [4.1 to 32] < Oral thrush 166 92% < 0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% < 0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case definition*** 360 86% < 0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Doks wasted 379 83% < 0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Doks wasted 379 83% < 0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < 38.0 degrees C 324 74% < 0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < 39.0 plable		4/9	1290	<0.001	5.0	[2.4 to 3.9]	3.4	[2.0 to 4.4]	<0.001
Pneumonia 114 74% <0.001 2.3 [1.5 to 3.5] 2.4 [1.5 to 3.7] < Night sweats 219 84% 0.001 1.5 [1.2 to 1.9] 1.5 [1.2 to 1.9] < Abscess / drainage of pus 103 64% 0.15 1.4 [0.9 to 2.1] 1.4 [0.89 to 2.1] 0  Clinical Signs  Oral Hairy leukoplakia 16 100% <0.001 * Shingles scar 86 98% <0.001 35.9 [8.8 to 147] 34.9 [4.8 to 255] < Skin Kaposi's sarcoma 44 98% <0.001 34.8 [8.8 to 147] 34.9 [4.8 to 255] < Skin Kaposi's sarcoma 27 96% 0.003 20.3 [2.7 to 150] 19.3 [2.6 to 143] 0  Oesophageal thrush** 61 93% <0.001 11.5 [4.2 to 32] 11.3 [4.1 to 32] < Oral thrush 166 92% <0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% <0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case definition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herry simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0  Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] <		520	710/	-0.001	2.0	[0.24=2.73	20	F2 2 to 2 61	< 0.001
Night sweats 219 84% 0.001 1.5 [1.2 to 1.9] 1.5 [1.2 to 1.9] < Abscess / drainage of pus 103 64% 0.15 1.4 [0.9 to 2.1] 1.4 [0.89 to 2.1] 0.  Clinical Signs Oral Hairy leukoplakia 16 100% <0.001 • Shingles scar 86 98% <0.001 35.9 [8.8 to 147] 34.9 [4.8 to 255] < Oral Kaposi's sarcoma 44 98% <0.001 34.8 [8.8 to 147] 34.9 [4.8 to 255] < Skin Kaposi's sarcoma 27 96% 0.003 20.3 [2.7 to 150] 19.3 [2.6 to 143] 0. Oesophageal thrush** 61 93% <0.001 11.5 [4.2 to 32] 11.3 [4.1 to 32] < Oral thrush 166 92% <0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% <0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case definition*** 360 86% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0. Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] <								. ,	< 0.001
Abscess / drainage of pus 103 64% 0.15 1.4 [0.9 to 2.1] 1.4 [0.89 to 2.1] 0.0 Clinical Signs  Oral Hairy leukoplakia 16 100% <0.001 ⋅ Shingles scar 86 98% <0.001 35.9 [8.8 to 147] 34.9 [4.8 to 255] < Oral Kaposi's sarcoma 44 98% <0.001 34.8 [8.8 to 147] 34.9 [4.8 to 255] < Skin Kaposi's sarcoma 27 96% 0.003 20.3 [2.7 to 150] 19.3 [2.6 to 143] 0.0 Cesophageal thrush** 61 93% <0.001 11.5 [4.2 to 32] 11.3 [4.1 to 32] < Oral thrush 166 92% <0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% <0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case definition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0.0 Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] <									
drainage of pus     103     64%     0.15     1.4     [0.9 to 2.1]     1.4     [0.89 to 2.1]     0.0       Clinical Signs       Oral Hairy       leukoplakia     16     100%     <0.001	•	219	84%	0.001	1.5	[1.2 to 1.9]	1.5	[1.2 to 1.9]	< 0.001
Clinical Signs         Oral Hairy         leukoplakia       16       100%       <0.001		103	64%	0.15	1.4	[0.9 to 2.1]	1.4	[0.89 to 2.1]	0.15
Oral Hairy leukoplakia 16 100% <0.001 • Shingles scar 86 98% <0.001 35.9 [8.8 to 147] 34.9 [4.8 to 255] < Oral Kaposi's sarcoma 44 98% <0.001 34.8 [8.8 to 147] 34.9 [4.8 to 255] < Skin Kaposi's sarcoma 27 96% 0.003 20.3 [2.7 to 150] 19.3 [2.6 to 143] 0 Oesophageal thrush** 61 93% <0.001 11.5 [4.2 to 32] 11.3 [4.1 to 32] < Oral thrush 166 92% <0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% <0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case (affinition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0 Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < ≥ 3 galpable									
Shingles scar       86       98%       <0.001       35.9       [8.8 to 147]       34.9       [4.8 to 255]       <         Oral Kaposi's sarcoma       44       98%       <0.001									
Oral Kaposi's sarcoma 44 98% <0.001 34.8 [8.8 to 147] 34.9 [4.8 to 255] < Skin Kaposi's sarcoma 27 96% 0.003 20.3 [2.7 to 150] 19.3 [2.6 to 143] 0  Oesophageal thrush** 61 93% <0.001 11.5 [4.2 to 32] 11.3 [4.1 to 32] < Oral thrush 166 92% <0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% <0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case definition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0  Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < Temperature ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < 3 palpable									
sarcoma       44       98%       <0.001	Shingles scar	86	98%	< 0.001	35.9	[8.8 to 147]	34.9	[4.8 to 255]	< 0.001
Skin Kaposi's sarcoma 27 96% 0.003 20.3 [2.7 to 150] 19.3 [2.6 to 143] 0.00   Oesophageal thrush** 61 93% <0.001 11.5 [4.2 to 32] 11.3 [4.1 to 32] < Oral thrush 166 92% <0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% <0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case definition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [1.2 to 22.8] 0.0   Temperature ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < ≥ 3 palpable	Oral Kaposi's								
sarcoma       27       96%       0.003       20.3       [2.7 to 150]       19.3       [2.6 to 143]       0         Oesophageal thrush**       61       93%       <0.001		44	98%	< 0.001	34.8	[8.8 to 147]	34.9	[4.8 to 255]	< 0.001
sarcoma       27       96%       0.003       20.3       [2.7 to 150]       19.3       [2.6 to 143]       0         Oesophageal thrush**       61       93%       <0.001	Skin Kaposi's								
Oesophageal thrush** 61 93% <0.001 11.5 [4.2 to 32] 11.3 [4.1 to 32] < Oral thrush 166 92% <0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% <0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case definition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0.0 Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < $\times$ 2 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < $\times$ 3 palpable	sarcoma	27	96%	0.003	20.3	[2.7 to 150]	19.3	[2.6 to 143]	0.004
Oral thrush 166 92% <0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% <0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case definition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0. Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < Temperature ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < ≥ 3 palpable									
Oral thrush 166 92% <0.001 10.4 [5.9 to 18.2] 10.1 [5.7 to 17.6] < Hair loss (not male pattern) 110 92% <0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case definition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0. Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < Temperature ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < ≥ 3 palpable	thrush**	61	93%	< 0.001	11.5		11.3	[4.1 to 32]	< 0.001
Hair loss (not male pattern) 110 92% <0.001 9.8 [4.9 to 19.5] 10.1 [5.1 to 20.3] < WHO case definition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0.0 Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < Temperature ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < ≥ 3 palpable		166	92%	< 0.001	10.4	[5.9 to 18.2]	10.1	[5.7 to 17.6]	< 0.001
$ \begin{array}{llllllllllllllllllllllllllllllllllll$						-			
WHO case definition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0.001 5.9 Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < Temperature $\geq 38.0 \text{ degrees C}  324  74\%  <0.001  2.7  [2.1 to 3.6]  2.6  [1.9 to 3.4] < 39 \text{ apalpable}$		110	92%	< 0.001	9.8	[4.9 to 19.5]	10.1	[5.1 to 20.3]	< 0.001
definition*** 360 86% <0.001 8.1 [5.8 to 11.3] 8.3 [5.0 to 11.7] < Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0.001 5.9 Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < Temperature ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < ≥ 3 palpable								-	
Looks wasted 379 83% <0.001 5.9 [4.4 to 7.9] 6.5 [4.8 to 8.8] < Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0. Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < Temperature ≥ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < ≥ 3 palpable		360	86%	< 0.001	8.1	[5.8 to 11.3]	8.3	[5.0 to 11.7]	< 0.001
Herpes simplex 16 88% 0.027 5.3 [1.2 to 23.6] 5.1 [1.2 to 22.8] 0.01 Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] <								-	< 0.001
Diffuse maculopapular rash 95 86% <0.001 5.3 [2.9 to 9.5] 5.1 [2.8 to 9.4] < Temperature $\geq 38.0$ degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < $\geq 3$ palpable									0.003
maculopapular rash       95       86%       <0.001       5.3       [2.9 to 9.5]       5.1       [2.8 to 9.4]       <         Temperature       ≥ 38.0 degrees C       324       74%       <0.001								t	
Temperature $\geq$ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < $\geq$ 3 palpable		95	86%	< 0.001	5.3	[2.9 to 9.5]	5.1	[2.8 to 9.4]	< 0.001
$\geq$ 38.0 degrees C 324 74% <0.001 2.7 [2.1 to 3.6] 2.6 [1.9 to 3.4] < $\geq$ 3 palpable		-				[]			*-T× 41
≥ 3 palpable		324	74%	< 0.001	2.7	[2.1 to 3.6]	2.6	[1.9 to 3.4]	< 0.001
		J		20.001		faut to 2101	2.0	Lan to Stril	40.001
	lymph nodes	256	75%	< 0.001	2.7	[2.0 to 3.7]	2.8	[2.1 to 3.9]	< 0.001
									< 0.001

Table 4. Predictors of HIV seropositivity

Adjusted Odds Ratios are adjusted for age, sex, urban residence, education level reached. Odds ratios for age groups relate to age 13-20 years, and are adjusted for sex, urban residence, literacy and education level reached.

<sup>\*</sup> Daily activity impaired = unable to perform normal activities over previous month

<sup>\*\*</sup> Oesophageal thrush diagnosed presumptively if oral thrush with painful dysphagia.

<sup>\*\*\*</sup> WHO case definition for AIDS surveillance [WHO, 1994] does not rely on an HIV test (unlike the expanded WHO case definition).